Riskpilot← Back to searchSign inGet full accessSelectImmune Pharma AB
ABDissolvedOrg 5591046874Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20172 employees
Revenue 2023
SEK 0
EBITDA margin
—
+40% vs 2022
Equity ratio
61.8%
Financial strength
Net profit 2023
SEK -8,6M
+39% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -8,2M | +40% |
| Net profit | SEK -8,6M | +39% |
| Total assets | SEK 5,1M | -61% |
| Equity | SEK 3,2M | -73% |
| Employees | 2 | — |
Legal name
SelectImmune Pharma AB
Org number
5591046874
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
15 mars 2017
Share capital
SEK 873 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Godaly, Gabriela Sofia Victoria i förening med en av Svanborg, Marianne Catharina Zetterberg, Jan Gustaf Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget ska bedriva konsultverksamhet inom medicin samt forskning och utveckling av läkemedel, särskilt inom området infektioner, ävensom idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — |
| EBITDA | −13 | −3 932 | −8 164 | −12 244 | −13 682 | −8 233 |
| Depreciation & amort. | −0 | −0 | −76 | −399 | −399 | −399 |
| EBIT | −13 | −3 932 | −8 240 | −12 643 | −14 081 | −8 632 |
| Net financials | — | — | — | — | — | 15 |
| Profit before tax | −13 | −3 932 | −8 240 | −12 643 | −14 081 | −8 617 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −13 | −3 932 | −8 240 | −12 643 | −14 081 | −8 617 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Total assets | 49 | 38 263 | 25 084 | 28 886 | 13 006 | 5 127 |
| Equity | 37 | 32 612 | 24 372 | 25 866 | 11 785 | 3 168 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 12 | 5 651 | 712 | 3 019 | 1 221 | 1 959 |
| Total debt | 12 | 5 651 | 712 | 3 019 | 1 221 | 1 959 |
EBITDA margin
-823300000.0%
This company
15.8%
Market median
-5210759594% vs market
20182023
Equity ratio
61.8%
This company
38.2%
Market median
+62% vs market
20182023
Return on equity
-272.0%
This company
18.4%
Market median
-1578% vs market
20182023
Net profit margin
-861700000.0%
This company
8.1%
Market median
-10638271705% vs market
20182023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182023
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20182023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-03-01 – 2018-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EC Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
PA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
GS Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AU Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
PO Chief Auditor | Chief Auditor | 2020 | — | — |
JG External Signatory | External Signatory | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SelectImmune Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ernst Carl Fredrik Herslow | Chief Executive Officer | 0 companies |
| Per Anders Jakob Testad | Chief Executive Officer | 0 companies |
| Gabriela Sofia Victoria Godaly | Chief Executive Officer | 0 companies |
| Ann Ulrika Gidner | Chief Executive Officer | 0 companies |
| Per Olof Henry Ranstam | Chief Auditor | 0 companies |
| Jan Gustaf Zetterberg | External Signatory | 0 companies |
| Nils Gustaf Magnus Nylén | Board of Directors | 0 companies |
| Carl-Johan Gustaf Wachtmeister | Board of Directors | 0 companies |
| Nils David Alexander Hagberg | Board of Directors | 0 companies |
| Ulla Helena Lomberg | Board of Directors | 0 companies |
| Karl Magnus Karlström | Board of Directors | 0 companies |
| Marianne Catharina Svanborg | Chairman | 0 companies |